Full-Time
Posted on 8/6/2025
Biopharmaceutical company developing neurodegenerative therapies
$275k - $325k/yr
Cambridge, MA, USA
Remote
U.S. remote role; not eligible from AK, AZ, HI, MI, TN. Travel to Cambridge, MA several times/yr.
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Amylyx Pharmaceuticals to present at the 25th Annual Needham Virtual Healthcare Conference. CAMBRIDGE, Mass.-(BUSINESS WIRE)-Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 15, 2026, at 8:45 a.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com. Contacts. Investors Lindsey Allen Amylyx Pharmaceuticals, Inc. +1 (857) 320-6244 [email protected] More News From Amylyx Pharmaceuticals, Inc. CAMBRIDGE, Mass.-( BUSINESS WIRE )-Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline," said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. "In 2026, our primary focus is on our Phase 3 LUCIDITY trial of av... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences...
Amylyx Pharmaceuticals has completed enrolment in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycaemia following Roux-en-Y gastric bypass surgery. The 16-week, double-blind, placebo-controlled study has randomised and dosed its final participant. The milestone positions Amylyx to potentially file for approval of a first-in-class GLP-1 receptor antagonist for a condition with no FDA-approved therapies. Topline results are expected in Q3 2026. Earlier trials showed consistent reductions in severe hypoglycaemic events. The company maintains a $317 million cash balance to support trial milestones but remains loss-making. Analyst forecasts project revenues of $107.8 million and earnings of $23.1 million by 2029, though estimates vary considerably.
Amylyx Pharmaceuticals has completed recruitment for its pivotal Phase 3 LUCIDITY trial of Avexatide for post-bariatric hypoglycemia and is shifting its core focus towards the drug whilst preparing for potential expedited regulatory submission once top-line data becomes available later this year. The company has also nominated AMX318, a GLP-1 antagonist, as a new development candidate. Trading at $14.11, Amylyx shares are up 23.6% year-to-date and 368.8% over one year, though down 60.7% over three years. With a 2025 net loss of $144.74 million and minimal revenue, Amylyx is streamlining legacy programmes and reallocating spending. The company has filed a universal shelf registration including $100.87 million tied to common stock, signalling potential future equity issuance.
TCG Crossover has acquired a 5.7% stake in Amylyx Pharmaceuticals, according to recent regulatory filings. The investment firm, through its Fund II and associated entities, now holds 6,243,812 shares of the biotechnology company. The filing classifies this as a passive investment, indicating no current intention to influence corporate strategy or management. The stake is based on 109.8 million total shares outstanding as of last October. For Amylyx, securing backing from established institutional investors typically contributes to shareholder base stability. The investment suggests professional capital allocators view the company's development projects favourably. Future stock performance will primarily depend on clinical trial outcomes, regulatory milestones and data releases from the company's pipeline.
Amylyx Pharmaceuticals Co-Chief Executive Joshua B Cohen exercised 200,000 stock options and sold 138,167 shares on 15-16 January for approximately $1.9 million. The sale was conducted to cover option costs and tax obligations, not as a discretionary decision. The transaction reduced Cohen's direct holdings by 3.93% to 3,379,465 shares, representing an estimated 4.07% insider ownership. The shares sold significantly exceeded his historical median sell size of 15,220 shares. Amylyx is a clinical-stage biotechnology company focused on neurodegenerative diseases and endocrine conditions. Its flagship therapy, AMX0035, has shown effectiveness in slowing ALS progression. The company's share price rose approximately 223% in 2025, with market capitalisation reaching $1.57 billion. It's also advancing avexitide, a phase three candidate for treating hypoglycemia.